@article{b8c512828ac54387bb685ee52576dc16,
title = "The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials",
abstract = "This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed) p = 0.2998; nmCRPC (confirmed) p = 0.0044; mCRPC (unconfirmed) p < 0.0001). Across the prostate cancer continuum, enzalutamide is well-tolerated and delays the negative impact that disease progression has on quality of life.",
keywords = "Anti-neoplastic agents, Cancer pain, Prostatic neoplasms, Quality of life, Treatment outcome",
author = "Bertrand Tombal and Arnulf Stenzl and David Cella and Yohann Loriot and Armstrong, {Andrew J.} and Karim Fizazi and Tomasz Beer and Sternberg, {Cora N.} and Maha Hussain and Cristina Ivanescu and Arijit Ganguli and Krishnan Ramaswamy and Fred Saad",
note = "Funding Information: Acknowledgments: Medical writing support was provided by Emily Ruzich, of IQVIA, and editorial assistance was provided by Folabomi Oladosu, Jane Beck, and Lauren Smith of Complete HealthVizion, funded by the study sponsors. Stefan Holmstrom and James Turnbull assisted in conceptualizing this study. Funding Information: Conflicts of Interest: B.T. reports honoraria from Astellas, Bayer, Janssen and Sanofi, and has acted in an advisory role for Amgen, Astellas, Ipsen and Takeda. A.S. has acted as an investigator, consultant or other advisory role for Alere, Amgen, Astellas, AstraZeneca, Aventis, BMS, Cepheid, CureVac, Ferring, GemeDX Bioscience, Immatics, Ipsen Pharma, Janssen, Johnson & Johnson, Karl Storz AG, Medivation, Roche, Stebatiotechnology, Synergo and Sanofi. In addition, A.S. has pending patents A290/99, AT00/0001:C-Trap and 2018/6579. D.C. reports grants and personal fees from Astellas and Janssen. Y.L. reports grants from Celsius, Janssen, MSD and Sanofi, as well as personal fees from Astellas, AstraZeneca, BMS, Janssen, MSD, Roche, Pfizer, Sanofi and Seattle Genetics. A.J.A. reports funding, personal fees or other advisory support from Active Biotech, Astellas, Bayer, BMS, Dendreon, Gilead Sciences, Janssen, Medivation, Novartis, Pfizer, Roche/Genentech and Sanofi. K.F. reports personal fees from Astellas, AstraZeneca, Bayer, CureVac, Janssen, Orion and Sanofi. T.B. reports grants from Alliance Foundation Trials, Astellas, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc, Harpoon Therapeutics, Janssen, Medivation, Sotio, Theraclone Sciences/OncoResponse and Zenith Epigenetics. In addition, T.B. reports personal fees from Arvinas, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Clovis Oncology, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer and Tolero, and reports stock ownership for Arvinas and Salarius Pharmaceuticals. C.N.S. reports grants and honoraria from Astellas, AstraZeneca, Clovis Oncology, Incyte, Medscape, Merck, Pfizer, Roche/Genentech, Sanofi-Genzyme and UroToday. M.H. reports grants from AstraZeneca, Bayer, Genentech and Pfizer, as well as personal fees from Astellas, Astra-Zeneca, Bayer, Daiichi Sankyo Company, Genentech, Medical Learning Institute PeerView, Pfizer, Physicians{\textquoteright} Education Resource, Phillips Gilmore Oncology, Projects in Knowledge, Research to Practice and Sanofi/Genzyme. C.I. is an employee of IQVIA and received funding from Astellas for consulting and analysis. A.G. is an employee of Astellas. K.R. is an employee of Pfizer and reports stock ownership for Johnson & Johnson and Pfizer. F.S. reports grants and personal fees from As-tellas, Bayer, Janssen and Sanofi. Funding Information: Funding: This study was funded by Astellas Pharma Inc. and Pfizer Inc., the co-developers of en-zalutamide. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).",
year = "2021",
month = dec,
doi = "10.3390/cancers13235872",
language = "English (US)",
volume = "13",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "23",
}
